version: "2.0"

intents:
  - greet
  - goodbye
  - affirm
  - deny
  - mood_great
  - mood_unhappy
  - bot_challenge
  - faq_symptoms
  - faq_vaccine
  - inquire_cases

entities:
  - state

responses:
  utter_greet:
    - text: "Hai! I am a COVID-19 Assistant here to help you find answers"

  utter_cheer_up:
    - text: "Here is something to cheer you up:"
      image: "https://i.imgur.com/nGF1K8f.jpg"

  utter_did_that_help:
    - text: "Did that help you?"

  utter_happy:
    - text: "Great, carry on!"

  utter_goodbye:
    - text: "Bye"

  utter_iamabot:
    - text: "I am a bot, powered by Rasa."

  utter_faq_symptoms:
    - text:
        COVID-19 affects different people in different ways. Most infected people
        will develop mild to moderate symptoms.Common symptoms:fever, tiredness, dry
        coughSome people may experience:aches and pains, nasal congestion, runny nose,
        sore throat, diarrhoea. On average it takes 5–6 days from when someone is infected
        with the virus for symptoms to show, however it can take up to 14 days
    - text:
        The virus can cause a range of symptoms, from ranging from mild illness
        to pneumonia. Symptoms of the disease are fever, cough, sore throat and headaches.
    - text:
        Most people infected with the COVID-19 virus will experience mild to moderate
        respiratory illness and recover without requiring special treatment. Older people,
        and those with underlying medical problems like cardiovascular disease, diabetes,
        chronic respiratory disease, and cancer are more likely to develop serious illness.
    - text:
        People with COVID-19 generally develop signs and symptoms, including mild
        respiratory symptoms and fever, on an average of 5-6 days after infection (mean
        incubation period 5-6 days, range 1-14 days). Most people infected with COVID-19
        virus have mild disease and recover.

  utter_faq_vaccine:
    - text:
        The safety and efficacy data from clinical trials of vaccine candidates are examined by Drug regulator of our country before granting the license for the same. Hence, all the COVID-19 vaccines that receive license will have comparable safety and efficacy.
    - text:
        It is absolutely necessary that everyone who has received the COVID-19 vaccine should continue to follow the COVID-19 appropriate behaviour
    - text:
        Two vaccines were granted emergency use authorization by the Central Drugs Standard Control Organization (CDSCO) in India, Covishield® (AstraZeneca's vaccine manufactured by Serum Institute of India) and Covaxin® (manufactured by Bharat Biotech Limited). Sputnik - V has been granted EUA in the month of April 2021.
    - text:
        The body responds to vaccination by making more than one type of antibodies to virus parts including spike protein. Therefore, all vaccines are expected to provide reasonable amount of protection against the mutated virus also. 

actions:
  - action_tell_cases

session_config:
  session_expiration_time: 60
  carry_over_slots_to_new_session: true
